Table 1.
Sociodemographic characteristics of HIV-infected children who are naïve to antiretroviral therapy and those who have experienced cART for at least six months, 2016–2018.
| Variable | cART Naïve (n = 105) | cART Experienced (n = 215) | p-Value |
|---|---|---|---|
| Male sex | 52.0% | 50.5% | 0.185 † |
| Age, median (IQR) | 9.0(5.0–12.5) | 12.0(8.1–14.1) | <0.001 ‡ |
| Age at HIV diagnosis, median(IQR) | 6.10(4.0–10.0) | ||
| HAZ, median (IQR) | −1.46(−2.41–(−0.66)) | −1.27(−1.99–(−0.21)) | 0.014 ‡ |
| WAZ, median (IQR) | −1.41(−2.51–(−0.80)) | −0.80(−1.50–0.12) | <0.001 ‡ |
| BAZ, median (IQR) | −1.16(−2.45–(−0.29)) | −0.95(−1.53–(−0.09)) | 0.022 ‡ |
| Stage 3 or 4 WHO clinical stage | 38.5% | 50.0% | 0.040 † |
| Log10 pVL, median(IQR) | 4.26(3.33–5.01) | 2.99(2.36–3.77) | <0.001 ‡ |
| Detectable pVL (>150 copies/mL) * | 95 (100) | 53(33.1) | <0.001 † |
| CD4 Count, Median (IQR), cells/mL | 330(217–719) | 754(518–1050) | <0.001 ‡ |
| Creatinine, Median (IQR), mg/dL | 0.60(0.40–0.70) | 0.60(46–0.70) | 0.876 ‡ |
| BUN, Median (IQR), mg/dL | 17.0(12.10–24.50) | 9.0(4.30–15.0) | <0.001 ‡ |
| ALT, Median (IQR), units/L | 26.0(19.0–36.5) | 21.0(16.0–32.0) | 0.003 ‡ |
| AST, Median (IQR), units/L | 39.0(32.2–53.0) | 32.0(24.5–41.0) | <0.001 ‡ |
| Hemoglobin, Median (IQR), mg/dL | 12.3(11.4–13.2) | 13.4(12.5–14.5) | <0.001 ‡ |
‡ Mann-Whitney test used to compare the medians; † Fisher’s Exact test was used; cART–combination antiretroviral therapy; BUN–Blood Urea Nitrogen; ALT–Alanine Aminotransferase; AST–Aspartate Aminotransferase; HAZ–Height for Age Z-core; WAZ–Weight for Age Z-core; BAZ–Body Mass Index for Age Z-core; WHO–World Health Organization; IQR–Interquartile range; * Ten children from the cART naïve group had insufficient sample and pVL could not be done.